Roche agrees to sell eczema drug rights to Dermira

04:07 EDT 9 Aug 2017 | Pharmaceutical Business Review

Dermira has signed a licensing agreement with Roche to secure exclusive rights to lebrikizumab, a monoclonal antibody targeting interleukin 13 (IL-13), for atopic dermatitis and all other indications.

Original Article: Roche agrees to sell eczema drug rights to Dermira


More From BioPortfolio on "Roche agrees to sell eczema drug rights to Dermira"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...